Efficacy of rabeprazole (Razo®) in the treatment of various clinical variants of GERD: results from the GERBERA study
Introduction. Gastroesophageal reflux disease (GERD) is extremely common in the structure of gastroenterological diseases. Aim. To conduct a prospective observational post-marketing study of rabeprazole (Razo®) 20 mg taking once daily in patients with non-erosive reflux disease (NERD) after 2 and 4...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Russo |
| Julkaistu: |
Remedium Group LLC
2022-05-01
|
| Sarja: | Медицинский совет |
| Aiheet: | |
| Linkit: | https://www.med-sovet.pro/jour/article/view/6857 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|